Skip to main content
Before treatment with PLUVICTO

A PSMA PET scan will check for PSMA+ cancer in your body

PET scan icon

If you have already been treated with other anticancer treatments and your doctor determines that PLUVICTO is an appropriate treatment, he/she will refer you to a radiation oncologist or nuclear medicine treatment facility to receive PLUVICTO.

  • A team of doctors will be working together to manage care of your PSMA+ metastatic castration-resistant prostate cancer
  • Laboratory tests will be performed within 3 days before your first treatment with PLUVICTO
During treatment with PLUVICTO

PLUVICTO is given once every 6 weeks for up to 6 treatments, depending on how your body responds

After treatment with PLUVICTO

Be sure to follow instructions given by your health care provider.

PSMA+, prostate-specific membrane antigen positive.

Important Safety Information

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer...
 

Approved Use

What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen­–­positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USE